CASC6: A Protein Targeted for Cancer Treatment (G101929083)

Target Name: CASC6

NCBI ID: G101929083

CASC6

Other Name(s): Cancer susceptibility 6 | cancer susceptibility 6 | Cancer susceptibility candidate 6 (non-protein coding) | Cancer susceptibility 6 (non-protein coding)

CASC6: A Protein Targeted for Cancer Treatment

Cancer Susceptibility 6 (CASC6) is a protein that is expressed in a variety of tissues throughout the body, including the brain, lungs, liver, and blood cells. It is a key regulator of cell growth and differentiation, and is involved in the development and progression of many types of cancer. Despite its importance, little is known about CASC6 and its potential as a drug target or biomarker.

In recent years, the use of drugs to treat cancer has become increasingly common. These drugs work by targeting specific proteins that are over-expressed or mutated in the cancer cells, in order to inhibit their growth or kill them off altogether. One of the challenges with developing effective cancer treatments is that many cancer cells are resistant to these drugs, and that they can evolve to evade their effects over time. This has led to a need for new approaches to cancer treatment, such as targeting CASC6 directly.

CASC6 is a protein that is expressed in a variety of tissues throughout the body, including the brain, lungs, liver, and blood cells. It is a key regulator of cell growth and differentiation, and is involved in the development and progression of many types of cancer. It is composed of two distinct chains, A and B, that are held together by a disulfide bond. The A chain consists of 112 amino acids, while the B chain consists of 114 amino acids.

CASC6 is involved in a variety of cellular processes that are important for cell growth and differentiation. It plays a role in the development and maintenance of the blood-brain barrier, which is a barrier that separates the brain from the surrounding blood vessels. The blood-brain barrier helps to protect the brain from harmful substances that could cause damage, but it also makes it difficult for drugs to reach the brain. CASC6 helps to regulate the formation of new blood-brain barrier cells, which is important for the brain to function properly.

CASC6 is also involved in the regulation of cell growth and differentiation. It helps to control the number of cells that have been generated, and it plays a role in the development of different types of tissues. For example, CASC6 helps to regulate the growth of blood cells, and it is involved in the development of the liver and the pancreas.

CASC6 is also involved in the regulation of cell death. It helps to ensure that cells die at the right time, which is important for the maintenance of tissue homeostasis. For example, CASC6 helps to regulate the death of cells that have been damaged by radiation, which can cause them to become cancerous.

CASC6 is also involved in the regulation of inflammation. It helps to control the amount of inflammation that occurs in the body, which is important for maintaining tissue health. For example, CASC6 helps to regulate the production of pro-inflammatory cytokines, which are important for immune responses.

In conclusion, CASC6 is a protein that is involved in a variety of cellular processes that are important for the development and progression of cancer. Its role in these processes makes it an attractive target for drug development, and its unique structure and expression patterns make it a valuable biomarker for cancer diagnosis and treatment. Further research is needed to fully understand the role of CASC6 in cancer, and to develop effective treatments.

Protein Name: Cancer Susceptibility 6

The "CASC6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CASC6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets